On Thursday, Ascendis Pharma A/S (NASDAQ:ASND) received a new coverage initiation from Stifel, starting with a Buy rating and a price target set at $200. Stifel's recommendation is based on the potential of Ascendis Pharma's product for Hypoparathyroidism, which has a Prescription Drug User Fee Act (PDUFA) date scheduled for August 14, 2024. This condition is seen as a significant commercial opportunity that could bolster the company's existing growth hormone business.
Ascendis Pharma's growth hormone product, Skytrofa, is anticipated to expand its market share through a transition from daily to weekly administration and possible label expansions. Despite the potential for competitive pressures, Stifel projects that Skytrofa could achieve peak sales of €1.3 billion, which aligns with or surpasses current consensus estimates.
The analyst's positive outlook extends beyond Hypoparathyroidism and Skytrofa to include potential developments within Ascendis Pharma's broader pipeline. Specifically, the TransCon CNP Phase 2/3 data for Achondroplasia, expected in the fourth quarter of 2024, could yield positive results, offering a competitive edge over similar data from BioMarin Pharmaceutical (NASDAQ:BMRN)'s Vosoritide.
Additionally, Stifel notes the promise of Ascendis Pharma's preclinical GLP-1 program, which is poised to enter clinical trials. The firm suggests that this could provide further upside to the company's prospects. The potential for peak sales of TransCon PTH in Hypoparathyroidism is estimated at a robust €3.0 billion, based on conservative penetration assumptions.
InvestingPro Insights
In light of Stifel's optimistic coverage initiation for Ascendis Pharma A/S, real-time data from InvestingPro provides additional context for investors. The company's market capitalization stands at a notable $7.6 billion, reflecting its significant presence in the biopharmaceutical industry. Despite not being profitable over the last twelve months, Ascendis Pharma has demonstrated a high gross profit margin of 85.61% in the same period, indicating strong revenue efficiency. Moreover, analysts have revised their earnings upwards for the upcoming period, suggesting a positive outlook on the company's financial performance.
Ascendis Pharma has experienced a large price uptick over the last six months, with a 31.94% total return, underscoring investor confidence in its growth trajectory. However, with short-term obligations exceeding liquid assets, investors should consider the company's liquidity when assessing risk. For those seeking more in-depth analysis, InvestingPro offers additional InvestingPro Tips that can help evaluate Ascendis Pharma's financial health and market potential. To access these tips and enhance your investment strategy, visit https://www.investing.com/pro/ASND and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 9 more tips available on InvestingPro, investors can gain a comprehensive understanding of Ascendis Pharma's financial landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.